Biological variation and reference intervals for circulating osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor kappa B ligand and high‐sensitivity C‐reactive protein

References

• Giachelli C. M., Steitz S. Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol 2000; 7: 615–22
   Web of Science ®Google Scholar
• Uede T., Katagiri Y., Iizuka J., Murakami M. Osteopontin, a coordinator of host defense system: a cytokine or an extracellular adhesive protein?. Microbiol Immunol 1997; 9: 641–8
   Web of Science ®Google Scholar
• Ashkar S., Weber G. F., Panoutsakopoulou V., Sanchirico M. E., Jansson M., Zawaideh S., et al. Eta‐1 (osteopontin): an early component of type‐1 (cell‐mediated) immunity. Science 2000; 5454: 860–4
   Web of Science ®Google Scholar
• O'Regan A. W., Nau G. J., Chupp G. L., Berman J. S. Osteopontin (Eta‐1) in cell‐mediated immunity: teaching an old dog new tricks. Immunol Today 2000; 10: 475–8
   Google Scholar
• Sodek J., Ganss B., McKee M. D. Osteopontin. Crit Rev Oral Biol Med 2000; 3: 279–303
   Google Scholar
• Petrow P. K., Hummel K. M., Schedel J., Franz J. K., Klein C. L., Muller‐Ladner U., et al. Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum 2000; 7: 1597–605
   Web of Science ®Google Scholar
• Ohshima S., Yamaguchi N., Nishioka K., Mima T., Ishii T., Umeshita‐Sasai M., et al. Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol 2002; 10: 2061–7
   Google Scholar
• Singhal H., Bautista D. S., Tonkin K. S., O'Malley F. P., Tuck A. B., Chambers A. F., et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 4: 605–11
   Google Scholar
• Hotte S. J., Winquist E. W., Stitt L., Wilson S. M., Chambers A. F. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone‐refractory prostate carcinoma. Cancer 2002; 3: 506–12
   Web of Science ®Google Scholar
• Kim J. H., Skates S. J., Uede T., Wong Kk K. K., Schorge J. O., Feltmate C. M., et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. J Am Med Assoc 2002; 13: 1671–9
   Web of Science ®Google Scholar
• Le Q. T., Sutphin P. D., Raychaudhuri S., Yu S. C., Terris D. J., Lin H. S., Lum B., Pinto H. A., Koong A. C., Giaccia A. J. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003; 1: 59–67
   Google Scholar
• Vogt M. H., Lopatinskaya L., Smits M., Polman C. H., Nagelkerken L. Elevated osteopontin levels in active relapsing‐remitting multiple sclerosis. Ann Neurol 2003; 6: 819–22
   Web of Science ®Google Scholar
• Comabella M., Pericot I., Goertsches R., Nos C., Castillo M., Blas N. J., et al. Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 2005; 1–2: 231–9
   Web of Science ®Google Scholar
• Hofbauer L. C., Heufelder A. E. Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis. Eur J Endocrinol 1998; 2: 152–4
   Web of Science ®Google Scholar
• Hofbauer L. C., Heufelder A. E. Role of receptor activator of nuclear factor‐kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 2001; 5–6: 243–53
   Web of Science ®Google Scholar
• Collin‐Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res 2004; 11: 1046–57
   Web of Science ®Google Scholar
• Pepys M. B., Hirschfield G. M. C‐reactive protein: a critical update. J Clin Invest 2003; 12: 1805–12
   Web of Science ®Google Scholar
• Nielen M. M., van Schaardenburg D., Reesink H. W., Twisk J. W., van de Stadt R. J., van der Horst‐Bruinsma I. E., et al. Increased levels of C‐reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 2004; 8: 2423–7
   Web of Science ®Google Scholar
• Shadick N. A., Cook N. R., Karlson E. W., Ridker P. M., Maher N. E., Manson J. E., et al. C‐reactive protein in the prediction of rheumatoid arthritis in women. Arch Intern Med 2006; 22: 2490–4
   Google Scholar
• Roberts W. L. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice. Laboratory tests available to assess inflammation – performance and standardization: a background paper. Circulation 2004; 25: e572–6
   Google Scholar
• Whicher J. T., Ritchie R. F., Johnson A. M., Baudner S., Bienvenu J., Blirup‐Jensen S., et al. New international reference preparation for proteins in human serum (RPPHS). Clin Chem 1994; 6: 934–8
   Google Scholar
• Fraser C. G., Harris E. K. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989; 5: 409–37
   Google Scholar
• Fraser C. G. Test result variation and the quality of evidence‐based clinical guidelines. Clin Chim Acta 2004; 1: 19–24
   Web of Science ®Google Scholar
• Wu C. Y., Wu M. S., Chiang E. P., Wu C. C., Chen Y. J., Chen C. J., et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut 2006
   Web of Science ®Google Scholar
• Vordermark D., Said H. M., Katzer A., Kuhnt T., Hansgen G., Dunst J., et al. Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 2006; 1: 207
   Web of Science ®Google Scholar
• Kon S., Maeda M., Segawa T., Hagiwara Y., Horikoshi Y., Chikuma S., et al. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 2000; 3: 487–98
   Google Scholar
• O'Regan A., Berman J. S. Osteopontin: a key cytokine in cell‐mediated and granulomatous inflammation. Int J Exp Pathol 2000; 6: 373–90
   Web of Science ®Google Scholar
• Hofbauer L. C., Schoppet M., Schuller P., Viereck V., Christ M. Effects of oral contraceptives on circulating osteoprotegerin and soluble RANK ligand serum levels in healthy young women. Clin Endocrinol (Oxf) 2004; 2: 214–19
   Web of Science ®Google Scholar
• Jung K., Lein M., Hosslin K., Grosse A., Roth S., Possinger K., et al. Osteoprotegerin and receptor activator of nuclear factor‐kappaB ligand (RANKL) in the serum of healthy adults. Int J Biol Markers 2002; 3: 177–81
   Web of Science ®Google Scholar
• Pulsatelli L., Dolzani P., Silvestri T., Caraceni P., Facchini A., Ravaglia G., et al. Soluble receptor activator of nuclear factor‐kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age‐associated diseases. Biogerontology 2004; 2: 119–27
   Web of Science ®Google Scholar
• Kudlacek S., Schneider B., Woloszczuk W., Pietschmann P., Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003; 6: 681–6
   Web of Science ®Google Scholar
• Liu J. M., Zhao H. Y., Ning G., Zhao Y. J., Chen Y., Zhang Z., et al. Relationships between the changes of serum levels of OPG and RANKL with age, menopause, bone biochemical markers and bone mineral density in Chinese women aged 20–75. Calcif Tissue Int 2005; 1: 1–6
   Web of Science ®Google Scholar
• Oh K. W., Rhee E. J., Lee W. Y., Kim S. W., Oh E. S., Baek K. H., et al. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women. Clin Endocrinol (Oxf) 2004; 2: 244–9
   Web of Science ®Google Scholar
• Trofimov S., Pantsulaia I., Kobyliansky E., Livshits G. Circulating levels of receptor activator of nuclear factor‐kappaB ligand/osteoprotegerin/macrophage‐colony stimulating factor in a presumably healthy human population. Eur J Endocrinol 2004; 3: 305–11
   Web of Science ®Google Scholar
• Chan B. Y., Buckley K. A., Durham B. H., Gallagher J. A., Fraser W. D. Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor‐kappa B ligand and osteoprotegerin in plasma and serum. Clin Chem 2003; 12: 2083–5
   Web of Science ®Google Scholar
• Hein G., Meister M. R., Oelzner P., Franke S. Vergleich der Serum‐ und Synovia‐Spiegel von sRANKL und OPG bei rheumatoider Arthirtis und nicht erosiven Arthritiden., Poster, vorgestellt beim 33 Kongress der D Ges für Rheumatologie, September 2005, Dresden
   Google Scholar
• Schedler J., Richter L., Braun A., Lehmann G., Hein G., Wolf G., et al. Osteoprotegerin, RANK‐ligand und 5b‐b TRAP bei Patienten mit Morbus Crohn. Poster P148 Z Gastroenterol, 43: 812
   Google Scholar
• Erlandsen E. J., Randers E. Reference interval for serum C‐reactive protein in healthy blood donors using the Dade Behring N Latex CRP mono assay. Scand J Clin Lab Invest 2000; 1: 37–43
   Web of Science ®Google Scholar
• Hutchinson W. L., Koenig W., Frohlich M., Sund M., Lowe G. D., Pepys M. B. Immunoradiometric assay of circulating C‐reactive protein: age‐related values in the adult general population. Clin Chem 2000; 7: 934–8
   Google Scholar
• Imhof A., Frohlich M., Loewel H., Helbecque N., Woodward M., Amouyel P., et al. Distributions of C‐reactive protein measured by high‐sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 2003; 4: 669–72
   Web of Science ®Google Scholar
• Chenillot O., Henny J., Steinmetz J., Herbeth B., Wagner C., Siest G. High sensitivity C‐reactive protein: biological variations and reference limits. Clin Chem Lab Med 2000; 10: 1003–11
   Web of Science ®Google Scholar
• Chambers J. C., Eda S., Bassett P., Karim Y., Thompson S. G., Gallimore J. R., et al. C‐reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 2001; 2: 145–50
   Web of Science ®Google Scholar
• Herbeth B., Siest G., Henny J. High sensitivity C‐reactive protein (CRP) reference intervals in the elderly. Clin Chem Lab Med 2001; 11: 1169–70
   Google Scholar
• Macy E. M., Hayes T. E., Tracy R. P. Variability in the measurement of C‐reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997; 1: 52–8
   Google Scholar
• Clark G. H., Fraser C. G. Biological variation of acute phase proteins. Ann Clin Biochem 1993; 373–6
   PubMed Web of Science ®Google Scholar
• Ockene I. S., Matthews C. E., Rifai N., Ridker P. M., Reed G., Stanek E. Variability and classification accuracy of serial high‐sensitivity C‐reactive protein measurements in healthy adults. Clin Chem 2001; 3: 444–50
   Google Scholar
• Franzini C. Need for correct estimates of biological variation: the example of C‐reactive protein. Clin Chem Lab Med 1998; 2: 131–2
   Web of Science ®Google Scholar
• Ledue T. B., Rifai N. Preanalytic and analytic sources of variations in C‐reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem 2003; 8: 1258–71
   Web of Science ®Google Scholar